Introduction
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious mucocutaneous blistering disorders that represent distinct entities within a spectrum of a single disease with common causes and mechanisms [1] [2] [3] . The incidences of SJS and TEN are estimated to be in the ranges of 1-6 and 1-3 cases per million person-years, respectively [4, 5] . Despite their rare occurrence, increased recognition and improved management, overall mortality remains significant, ranging from 1 to 10% for SJS and from 20 to 40% for TEN, respectively [6] [7] [8] [9] . In contrast, non-life-threatening dermatologic toxicities such as alopecia, nail changes, or rashes secondary to anticancer drugs are frequently reported, with well-described incidences, occurring in the majority of patients with some agents [10] . Moreover, although the association of various anticancer drugs with rare, yet clinically significant, life-threatening serious adverse events (SAEs) such as SJS or TEN has been anecdotally reported, the association has not been examined systematically. In the clinical realm, the putative association of oncology drugs with SJS or TEN may lead to physician and patient distress with consequent alterations in therapy, all of which may preclude additional dosing and affect clinical outcome.
There are various approaches to recognizing an association and assessing the risk between drugs and SAEs [11] . Information obtained from clinical trials and case reports may serve as one step in identifying a potential association. However, interpretation of such data for association is limited, and epidemiologic studies with sufficient data are usually necessary to identify associations and establish causality [11] . In addition to these traditional methods, various data-mining algorithms have been designed to aid the assessment of rapidly growing databases of spontaneously reported SAEs [12] . The United States Food and Drug Administration Adverse Event Reporting System (FAERS) utilizing MedWatch represents one such database that can be analyzed utilizing data-mining algorithms [13] . Although this method may not be sufficient to identify true associations, and particularly does not establish causality, it does serve as an additional tool to identify disproportionality in rates of reports that may warrant further investigation [14] . This study aimed to examine the relationship between anticancer agents and SJS or TEN by analyzing data from peer-reviewed published literature as well as the FAERS database.
Materials and methods
A literature search was performed through June 2013 (Ovid from 1950 and PubMed from 1948) using the terms Stevens-Johnson syndrome, toxic epidermal necrolysis, cancer drug therapy, and chemotherapy drugs. In addition, each anticancer agent reported in this paper was searched separately using appropriate terms. Ovid was utilized to accomplish an Embase search. We included only reports with anticancer drugs used specifically for the treatment of any cancer, except when such information was not provided. Histologic confirmation of SJS or TEN was not required for a report to be included in the results. Primary case reports and reports from clinical trials, or as part of postmarketing surveillance, were included in the results. All published peer-reviewed literature from the search was reviewed (reports were limited to the English language only with inclusion of selected non-English reports with English language abstracts) to identify drugs that were administered within 8 weeks of rash onset and/or concomitantly with the anticancer agent to which SJS/TEN was attributed. Other parameters such as concomitant radiotherapy and SJS/TEN outcomes were noted when available. In addition, as part of the Research on Adverse Drug Events and Reports project [15] , the FAERS database was searched for reports of SJS and TEN in association with anticancer agents as suspect drugs from 1968 through August 2012 (the most recent date for available FAERS data release) [16] .
Proportional reporting ratios (PRR) (PRR > 2, N > 3) and empirical Bayes geometric mean (EBGM) lower 95% confidence interval (CI) (EBGM 0.05 > 2, N > 3) were used as thresholds, constituting signals for disproportionate reporting of SJS or TEN for the selected anticancer drugs [12] . Data from the FAERS or other voluntary adverse event reporting system can be used to estimate whether a particular adverse event (AE) for a drug may be a 'signal' that the event occurs at a greater frequency among patients receiving the drug than would be expected by chance. There are several estimates that are commonly used and all use a similar methodology [12, 17, 18] . The PRR is the simplest and easiest to perform. The PRR is a statistical aid based on the proportionate approach on the basis of the stability of a large database. It involves calculation of the proportions of specified reactions for drugs of interest where the comparator is all other drugs in the database. Judgment of whether or not there is a signal and its strength is made on the basis of three pieces of information: (a) the PRR value and the 95% CI of the PRR, (b) the w 2 -value for the 2 Â 2 table, and (c) the number of cases reported. A signal is defined as a PRR of 2 or greater, a w 2 of at least 4, and three or more cases [17] .
An alternative is the EBGM, which is a quantitative method that decreases the relative importance of small numbers of reports that may be subject to greater statistical variability. Thus, EBGM decreases the signalto-noise ratio and provides a value that is less prone to false-positive signals [17] . Similar to the PRR, the EBGM mean values with 95% CIs are used to determine whether the number of cases in adverse event reporting system were relatively greater than for other drugs. If the EBGM CI at the 0.05 cutoff is greater than 2 and the number of cases is greater than 1, the signal is considered positive [14] .
Limitations
The limitations of the PRR and EBGM stem from the voluntary nature of adverse drug reaction reporting to the FDA. It is reported that fewer than 10% of adverse drug reactions are reported to spontaneous reporting systems such as MedWatch [19] . Reasons given by health professionals such as lack of awareness and lack of time, are associated with under-reporting [19] . Additional factors such as publicity associated with a specific adverse drug reaction, its seriousness, market size, and the inability to verify a drug/reaction relationship also impact the likelihood of the event being added to the system [20] . As PRR/EBGM represent an estimate of the comparative reporting rates for specific reactions to individual drugs, these rates may be affected by under-reporting that may be disproportionate between drugs [12, 17] . Therefore, the PRR/EBGM is not used as definitive evidence, but as a finding that, with supporting information, signals that a relationship between the drug and reaction exists. Additional factors such as consistency of the event descriptions and causality indicators (e.g. timing between exposure and event, dechallenge, rechallenge, blood levels), and biological explanation of the event should be used to verify the signal-event relationship [21] .
The FAERS database search methodology was based on the SJS and TEN reaction terms and all anticancer drug names. MedWatch reports included those in which anticancer agents were used to treat cancer or other noncancer diseases. Drugs used to treat cancer symptoms (e.g. pain) or adverse events of treatment (e.g. antinausea agents, infection) were not included in the FAERS searches. Further, the anticancer agent had to be listed as the primary or secondary suspect drug in FAERS, as determined by the reporter. Anticancer drugs listed as concomitant drugs in the MedWatch report were therefore excluded.
Results
A search of peer-reviewed literature yielded 46 reports of SJS in association with 18 anticancer agents . Similarly, 37 reports of TEN associated with 22 anticancer agents were identified [46, (Table 1) . A majority of SJS or TEN reports were in published literature. However, one TEN and 11 SJS reports associated with lenalidomide in patients with an underlying malignancy were reported to the pharmaceutical company in the setting of a published clinical trial [46] . SJS in association with docetaxel [31] (N = 1), tegafur-gimeraciloteracil potassium (TS-1) [47] (N = 1), methotrexate [34] (N = 2), gemcitabine [38] (N = 1), and fludarabine [42] (N = 1), and TEN in association with bivatuzumab mertansine [83] (N = 1) and treosulfan [84] (N = 1) were also reported in the setting of clinical trials. In 31 reports of SJS, patients were exposed to other drugs either concomitantly or within 8 weeks of the anticancer agent(s), but before the reaction (Table 2) . Similarly, in 27 TEN reports, exposure to other drugs and/or radiation was reported ( Table 3) . Among SJS reports, the outcome was available in 38 reports, nine of which were fatal. Five (63%) of the nine reports of fatality were attributed to SJS. Similarly, the outcome was available for 38 TEN reports, among which there were 16 (50%) deaths, with 13 (41%) attributed to TEN.
Search of the FAERS database yielded 2098 reports of SJS and 1555 reports of TEN associated with anticancer drugs. Of these, six FDA-approved drugs were reported at rates sufficient to produce significant signals (Table 4 ). Among the six chemotherapies with significant signals for TEN, reports for two (chlorambucil and procarbazine) were also identified in the literature. In contrast, all the anticancer agents that were identified in peer-reviewed literature, except lenalidomide, bivatuzumab mertansine, TS-1, peplomycin, and mithramycin, were also found in the FAERS database in association with SJS or TEN. However, these agents did not satisfy safety signal criteria (PRR > 2, N > 3 and EBGM 0.05 > 2, N > 3) and were not included in results. Table 5 shows the other cancer drugs reported as suspect drugs for TEN and/or SJS, but the number of cases was insufficient to result in significant signals.
For the anticancer drugs identified in the FAERS database (Table 4 ) associated with fewer than 10 adverse reaction reports and a significant signal, we further examined the reports for evidence of concomitantly administered drugs. In all cases except for one report of bendamustine associated with SJS, patients were exposed to other drugs, including those commonly associated with SJS/TEN, such as allopurinol, sulfonamide antibiotics, anticonvulsants, and NSAIDs.
Discussion
SJS and TEN are serious and potentially fatal disorders involving mucosal and cutaneous tissue that are characterized by extensive epidermal detachment associated with keratinocyte necrosis. Their classification is based on the percentage of total body surface area (TBSA) of epidermal detachment [3] . Involvement of less than 10% of TBSA is termed SJS, whereas epidermal detachment greater than 30% is characterized as TEN. SJS/TEN overlap syndrome defines cases that affect between 10 and 30% of TBSA [3] . There is typically a prodromal period with flu-like symptoms, followed by onset of rash. Characteristic erythematous dusky-red macules typically involve the trunk, neck, face, and extremities. Histological analysis shows full-thickness epidermal necrosis, often with dermal-epidermal attachment. It should be emphasized that histology is rarely diagnostic in itself, but is rather used as an aid to confirm the clinical picture. Greater than 90% of patients have involvement of oral, ocular, and genital mucosa [96, 97] . In the past, SJS and TEN were conceptualized to represent a part of the spectrum including clinical entities such as erythema multiforme major (EMM) and the two terms (SJS and EMM) were used interchangeably. It is now widely accepted, however, that SJS and TEN differ from EMM both in clinical presentation and in underlying etiologies [98] . Where it was indistinguishable in the past, these reports have been included for review.
Drugs are still the predominant cause of SJS, ranging from 50 to 80%, with other less common etiologies including infection, vaccination, and chemical exposure [96, 99] . Similarly, at least 80% of TEN cases are associated with drug exposure [99] . The most frequent suspect drugs for SJS/TEN are sulfonamide antibiotics, anticonvulsants, NSAIDs, and allopurinol [4, [100] [101] [102] .
Our search of peer-reviewed literature showed multiple cases reporting a potential association of anticancer drugs with SJS and TEN, including conventional cytotoxic and novel targeted agents ( Table 1 ). The interpretation of these results, however, is not without limitations and should be performed with caution. Among identified reports in our study, 14 were published [33] [34] [35] [36] 45, 57, 75, 77, 78, 80, [85] [86] [87] [88] before the introduction of the currently used classification system, which is based on the degree of BSA involvement, and would have been categorized differently at present. Moreover, the diagnosis was made on clinical grounds in the majority of cases, without a histopathologic confirmation. In a case of interleukin-induced TEN, the biopsy showed bullae underneath the stratum corneum without a true dermoepidermal separation, and the authors categorized this as a 'TEN-like reaction' [57] . In another case, the diagnosis of TEN in association with chlorambucil was made despite the histopathologic findings of chronic vasculitis.
The main difficulty in attempting to identify anticancer therapies that may potentially serve as triggers stems from the frequent coadministration of not only multiple anticancer agents but also drugs that are known to have strong associations with these cutaneous reactions (e.g. sulfonamide antibiotics, anticonvulsants, allopurinol). In the majority of published case reports, patients were exposed to multiple agents (Tables 2 and 3 ). In fact, in a case of TEN in the setting of cladribine therapy, intrinsic imputability (possible cause between drug and clinical event), scores were 'likely' for concomitantly administered sulfonamide antibiotics. Similarly, in one case of SJS developing during therapy with imatinib, [34] Methotrexate Dexamethasone, vincristine, leucovorin, L-asparaginase c , or 6-mercpatopurine f Giaccone et al. [35] Bleomycin Cisplatin, vinblastine Brodsky et al. [36] Bleomycin Cisplatin, vincristine, metamizole sodium (NSAID) Newman et al. [39] Topical nitrogen mustard Naproxen a , estrogen a , triamterene/hydrochlorothiazide a Hiraki et al. [40] Paclitaxel Carboplatin Lowndes et al. [41] Rituximab Chlorpheniramine Sarma [43] d Temozolomide and radiotherapy Phenytoin a,b , diclofenac a,b , radiation, dexamethasone Talamonti et al. [38] No specifically presumed culprit Gemcitabine, 5-FU, radiation Sendur and Kilickap [44] Capecitabine Cyclophosphamide c , doxorubicin c , fluorouracil c Jameson and Solanki [45] Etoposide Methotrexate, cyclophosphamide b , doxorubicin b , vincristine b , acetaminophen b , codeine b , compazine b Castaneda et al. [46] e Bortezomib in one case Dexamethasone (8 reports), allopurinol (2), moxifloxacin (1), levofloxacin (1), bortezomib (2), cyclophosphamide (1) Siniscalchi et al. [91] Lenalidomide in combination with dexamethasone Dexamethasone Allegra et al. [92] Lenalidomide in combination with prednisolone Prednisolone Lambertini et al. Continuation and/or reinstitution of these drugs after resolution of SJS/TEN did not induce a skin reaction. c Administered shortly before onset of skin toxicity but difficult to establish the precise time of administration in relation to the onset of the rash. d SJS/TEN overlap. e Eleven reports. f TEN-like reaction. according to Naranjo's algorithm [103] (a questionnaire designed for determining the causality in evaluation of an adverse reaction to a drug), SJS was 'possible' because of imatinib and 'probable' because of lansoprazole [23] . It is noteworthy that in all four cases of TEN associated with thalidomide, systemic corticosteroids were administered [65] [66] [67] [68] . Although corticosteroids have been reported as common triggers of SJS/TEN, their role as triggers is not clearly defined and there is a high potential for confounding [101] . However, a recently introduced algorithm of drug causality for epidermal necrolysis showed corticosteroids to be 'probably causal' in their relation to SJS/TEN [104] . Although multiple authors have attempted to attribute reactions to a particular anticancer agent either alone or in combination with other agents, causality remains difficult to ascertain.
Cancer patients often have comorbidities and multiorgan involvement by the underlying disease, which add to the overall complexity of each individual case analysis. It is also likely that in some cases, interaction between different anticancer agents may contribute toward the development of SJS/TEN. To improve our ability to optimally interpret case reports, thorough documentation of clinical history, renal and hepatic functions, and exposure to all drugs with precise dates in chronological order, when possible, should be performed. In addition, the process of identifying the offending agent requires knowledge of the individual drug's and relevant metabolite's half-life and the temporal relationship with the onset of rash.
Several cases in which no other concomitant drugs were reported and an anticancer agent was presumed to be the offending agent were also identified. This was particularly noted with imatinib-associated SJS, where in five of eight cases, it was the only agent to which the patient was exposed [22, 24, 25, 28, 50] . However, although case reports may heighten our suspicion of a specific association, by themselves, they are insufficient to establish causality [11] . Further, in many instances, insufficient clinical information may be provided, thereby limiting detailed analyses. In the identified published case reports, management strategies ranged from only supportive care to various combinations of systemic steroids, intravenous immunoglobulin therapy, and/or systemic antibiotics, which is consistent with the generally accepted approach to the treatment of SJS/TEN. In many cases, granulocyte colony stimulating factor was administered for concomitant neutropenia, which is a frequent complication of chemotherapy treatment. For cases where outcome was available, estimated mortality attributed to SJS and TEN was 16 and 40%, respectively, which reflects mortality to these syndromes [6] [7] [8] [9] .
FAERS utilizes MedWatch as a voluntary adverse event reporting system that is primarily directed toward postmarketing surveillance. AEs associated with prescription and over-the-counter FDA-approved drugs, biologics, medical devices, and nutritional products are reported using MedWatch. Despite the availability of the FAERS database for reporting and obtaining information on a variety of adverse effects from drugs, biologics, and nutritional products, its interpretation is not without limitations. First, duplicate reports are possible in the case of a single drug reaction. To detect duplicate reports for a single drug reaction, patient demographics (age, sex), date of reporting, reported diagnosis, outcomes, and patients' concomitant drug lists were assessed. Duplicate reporting within a single drug/reaction was not identified for any of the drugs that fulfilled our safety signal criteria (Table 4 ). In addition, some patients had both SJS and TEN reactions reported. In these situations, the reports were included in the analysis of both SJS and TEN drugs. Second, calculations of incidence, for example, cannot be carried out on the basis of these data. This is partially because it is not mandatory to report adverse drug events or to establish causality before reporting to FAERS database. Also, utilization data are not available in the FAERS. Both healthcare workers and consumers can submit reports; thus, data are often incomplete for appropriate analysis [105] , and may not consistently include a listing of all concomitantly administered drugs. Given these limitations, PRR and EBGM are accepted methods for identification of signals from FAERS data [12] .
Using our predefined thresholds for signals of disproportionate reporting, we have identified multiple anticancer drugs reported in association with SJS/TEN in the MedWatch database (Table 4 ). The majority of these agents, however, were not found in association with SJS/TEN in our search of the peer-reviewed literature. This discrepancy may be partially because our search of the FAERS database included chemotherapy drugs used to treat both cancer and noncancer diseases, whereas our search of the literature was limited to cases of cancer treatment. Moreover, several studies have reported a significant and widespread under-reporting of drug adverse effects in healthcare, which has been estimated to exceed 90% [19, 106, 107] . The discrepancy in the number of cases between the sources used in our search may reflect the existing underlying inconsistencies and inadequacy of reporting in general. The chosen threshold for our data-mining algorithms (PRR > 2, N > 3 and EBGM 0.05 > 2, N > 3) may be too 'sensitive', resulting in an increased number of identified associations that may not necessarily have clinical significance. To further investigate potential confounding factors, we explored whether other drugs, including those commonly associated with SJS or TEN, were concomitantly administered with anticancer agents that were associated with less than 10 cases of SJS or TEN. With the exception of one case of SJS associated with bendamustine, other coadministered drugs or anticancer therapies were reported for each case. In many instances, patients were exposed to drugs with an established association with SJS or TEN, such as antiepileptic agents, sulfonamide antibiotics, and allopurinol. Thus, the interpretation of these cases is difficult and the degree to which anticancer agents contributed toward the development of an AE is uncertain. These results are similar to what we observed in peer-reviewed literature. This highlights the difficulty in assessing potential offending agents in cancer patients, as in most cases there is exposure to multidrug regimens that may include the most common causes of SJS/TEN such as allopurinol and sulfonamide antibiotics.
Published case reports and data-mining algorithms from FAERS should not be utilized for defining specific associations in a vacuum. The associations identified should be assessed for pathologic mechanisms and verification using comprehensive patient care data sets. Our objective is to highlight an area in oncology that has not been systematically investigated thus far, and perhaps identify specific anticancer drugs having disproportionally increased frequency in association with SJS or TEN. It has been shown previously that data-mining algorithms may have the advantage of identifying reported associations before their appearance and recognition in the published literature B30% of time [14] . Even if a significant signal is detected after reports have started circulating in the published literature, these data may also serve as an additional method for further defining the level of suspicion [14] .
It is critical to establish causality as attribution to drugs is made erroneously in up to 24% of patients with a suspected cutaneous drug reaction [108] . This flawed attribution has been shown clearly in the oncology clinical research realm, in which up to 50% of AEs attributed to a study drug were reported in the placebo arm of a trial [109] . Directing our attention to specific anticancer agents with the help of data-mining algorithms or a critical review of the published literature helps identify those that may warrant further investigation. This knowledge can result in earlier consideration of certain anticancer drugs in the differential diagnosis of a patient with SJS/TEN. Making a timely and a correct diagnosis can facilitate discontinuation of a suspected drug, in which case morbidity associated with reactions may be reduced [96] . In contrast, correctly establishing a negative Life-threatening dermatologic adverse events Rosen et al. 231
attribution will allow patients to receive additional necessary therapy. All of this would be expected to optimize attribution and safety in both clinical trials and patient care.
